Teva reports no PDSS events with olanzapine LAI in schizophrenia trial
PositiveFinancial Markets
Teva Pharmaceuticals has announced that its recent trial of olanzapine long-acting injection (LAI) for schizophrenia showed no reported PDSS events. This is significant as it suggests a favorable safety profile for the medication, potentially offering new hope for patients struggling with this mental health condition. The absence of adverse events could lead to increased confidence among healthcare providers in prescribing this treatment.
— Curated by the World Pulse Now AI Editorial System